89 related articles for article (PubMed ID: 27249763)
1. Issues on the Use of White Blood Cell Growth Factors in Oncology Practice.
Lyman GH
Am Soc Clin Oncol Educ Book; 2016; 35():e528-32. PubMed ID: 27249763
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
Kearney N; Friese C
Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
[TBL] [Abstract][Full Text] [Related]
3. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
4. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based use of colony-stimulating factors in elderly cancer patients.
Lyman GH; Kuderer N; Agboola O; Balducci L
Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
7. Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer.
Agiro A; DeVries A; Malin J; Fisch MJ
J Natl Compr Canc Netw; 2018 Feb; 16(2):162-169. PubMed ID: 29439177
[No Abstract] [Full Text] [Related]
8. A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.
Lyman GH; Poniewierski MS
J Natl Compr Canc Netw; 2017 Dec; 15(12):1543-1550. PubMed ID: 29223991
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
10. Real-World Conundrums and Biases in the Use of White Cell Growth Factors.
Smith TJ; Hillner BE
Am Soc Clin Oncol Educ Book; 2016; 35():e524-7. PubMed ID: 27249762
[TBL] [Abstract][Full Text] [Related]
11. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
12. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
Lyman GH
Curr Opin Hematol; 2011 Jan; 18(1):1-10. PubMed ID: 21042215
[TBL] [Abstract][Full Text] [Related]
13. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
14. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
15. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
Abernethy AP; Barbour SY; Uronis H; Zafar SY; Coan A; Rowe K; Pupa MR; Wheeler JL; Herndon JE
Support Care Cancer; 2009 Jun; 17(6):735-44. PubMed ID: 19096882
[TBL] [Abstract][Full Text] [Related]
16. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
17. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N; Tanaka S; Takahata T; Sato A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
19. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
20. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
